Astrazeneca Plc $AZN Shares Acquired by GC Wealth Management RIA LLC

GC Wealth Management RIA LLC increased its holdings in Astrazeneca Plc (NYSE:AZN) by 8.8% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 35,401 shares of the company’s stock after acquiring an additional 2,876 shares during the quarter. GC Wealth Management RIA LLC’s holdings in Astrazeneca were worth $3,254,000 as of its most recent filing with the SEC.

Several other institutional investors have also modified their holdings of the business. Bank of America Corp DE lifted its stake in shares of Astrazeneca by 4.7% in the third quarter. Bank of America Corp DE now owns 32,633,139 shares of the company’s stock worth $2,503,614,000 after acquiring an additional 1,461,786 shares in the last quarter. Fisher Asset Management LLC lifted its stake in shares of Astrazeneca by 2.3% in the third quarter. Fisher Asset Management LLC now owns 21,162,724 shares of the company’s stock worth $1,623,604,000 after acquiring an additional 466,745 shares in the last quarter. Dimensional Fund Advisors LP lifted its stake in shares of Astrazeneca by 9.4% in the third quarter. Dimensional Fund Advisors LP now owns 6,805,896 shares of the company’s stock worth $521,517,000 after acquiring an additional 582,183 shares in the last quarter. Holocene Advisors LP lifted its stake in shares of Astrazeneca by 41.8% in the third quarter. Holocene Advisors LP now owns 6,129,194 shares of the company’s stock worth $470,232,000 after acquiring an additional 1,807,565 shares in the last quarter. Finally, Ameriprise Financial Inc. lifted its stake in shares of Astrazeneca by 13.1% in the third quarter. Ameriprise Financial Inc. now owns 5,707,561 shares of the company’s stock worth $438,342,000 after acquiring an additional 660,569 shares in the last quarter. Institutional investors and hedge funds own 20.35% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on AZN shares. Citigroup started coverage on Astrazeneca in a research note on Tuesday, January 27th. They issued a “buy” rating on the stock. Barclays restated an “overweight” rating on shares of Astrazeneca in a research note on Tuesday, January 6th. Deutsche Bank Aktiengesellschaft restated a “sell” rating on shares of Astrazeneca in a research note on Friday, February 6th. Morgan Stanley restated an “overweight” rating on shares of Astrazeneca in a research note on Wednesday, April 8th. Finally, TD Cowen restated a “buy” rating on shares of Astrazeneca in a research note on Wednesday, March 18th. Eight investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $102.67.

Key Astrazeneca News

Here are the key news stories impacting Astrazeneca this week:

• Positive Sentiment: AstraZeneca beat Q1 estimates and reaffirmed its 2026 outlook — Q1 EPS $2.58 vs. $2.53 est.; revenue $15.29B vs. $14.74B est. Management highlighted oncology and rare-disease strength, which underpinned the maintained guidance and explains the positive market reaction. Article Title
• Positive Sentiment: AstraZeneca exercised its option to license PTX-299 from Pinetree Therapeutics (an EGFR bispecific antibody degrader), expanding its oncology pipeline; the option exercise triggers a $25M payment to Pinetree — a sign AZN is investing in next‑gen targeted therapies. Article Title
• Positive Sentiment: UK investment: AstraZeneca will invest £300M (~$405M) in UK sites, reinforcing production and R&D capacity and giving political/regulatory goodwill that can support long-term operations. Article Title
• Neutral Sentiment: Analyst and media commentary: bullish analyst pieces and investor decks underline long‑term oncology-led growth (Seeking Alpha / MarketBeat coverage), but these are reiterations rather than new catalysts. Article Title
• Neutral Sentiment: Participation in FDA pilot for “real‑time” trials with Amgen/AZ could speed development cycles long-term, but this is an early-stage regulatory/operational play without immediate revenue impact. Article Title
• Negative Sentiment: Erste Group trimmed its FY2026 EPS forecast slightly to $10.30 from $10.44 — a minor downgrade that signals some analyst caution despite the beat; the revision is small and sits near consensus ($10.27), so its near-term market impact is limited.

Astrazeneca Stock Performance

Shares of NYSE AZN opened at $185.60 on Thursday. The company has a market cap of $287.85 billion, a price-to-earnings ratio of 31.97, a PEG ratio of 1.42 and a beta of 0.35. Astrazeneca Plc has a 52-week low of $132.32 and a 52-week high of $212.71. The company has a debt-to-equity ratio of 0.51, a quick ratio of 0.72 and a current ratio of 0.94.

Astrazeneca (NYSE:AZN) last posted its earnings results on Wednesday, April 29th. The company reported $2.58 EPS for the quarter, beating the consensus estimate of $2.53 by $0.05. The company had revenue of $15.29 billion during the quarter, compared to analyst estimates of $14.74 billion. Astrazeneca had a return on equity of 31.57% and a net margin of 17.41%. On average, analysts anticipate that Astrazeneca Plc will post 10.27 EPS for the current year.

Astrazeneca Dividend Announcement

The business also recently announced a dividend, which was paid on Monday, March 23rd. Stockholders of record on Friday, February 20th were issued a dividend of $1.595 per share. The ex-dividend date of this dividend was Friday, February 20th. This represents a dividend yield of 156.0%. Astrazeneca’s dividend payout ratio is 74.83%.

Astrazeneca Profile

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.